IMV Inc. is a clinical-stage biopharmaceutical company developing a novel class of cancer vaccines based on DPX®, our immune-educating technology platform. DPX is designed to inform a specific, coordinated and persistent anti-tumor immune response, improving the lives of patients with solid or hematological cancers. DPX can package a wide range of bioactive molecules in a single formulation to incite the tumor-killing function of multiple, distinct immune cell subtypes. IMV’s lead therapeutic candidate, maveropepimut-S (MVP-S), is a DPX-based cancer vaccine that delivers antigenic peptides from survivin, a well-recognized cancer antigen commonly overexpressed in advanced cancers. MVP-S also delivers an innate immune activator and a universal CD4 T cell helper peptide. Together, these elements are designed to foster maturation of antigen presenting cells as well as robust activation of CD8 T cell effector and memory function that drive a targeted, sustained immune response. In our clinical trials, MVP-S treatment has been well tolerated and has demonstrated favorable clinical outcomes in multiple cancer indications as well as the activation of a targeted and sustained, survivin-specific anti-tumor immune response. MVP-S is administered in very low doses approximately once every two months, which drives a persistent immune attack on tumor cells. For more information, visit https://www.imv-inc.com and connect with us on Twitter and LinkedIn.
Company profile
Ticker
IMVIQ
Exchange
Website
CEO
Frederic Ors
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Immunovaccine Inc.
SEC CIK
Corporate docs
IMVIQ stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
22 Sep 23
F-10POS
Automatic registration of securities (post-effective amendment, Canada)
22 Sep 23
F-10POS
Automatic registration of securities (post-effective amendment, Canada)
22 Sep 23
F-10POS
Automatic registration of securities (post-effective amendment, Canada)
22 Sep 23
S-8 POS
Registration of securities for employees (post-effective amendment)
22 Sep 23
S-8 POS
Registration of securities for employees (post-effective amendment)
22 Sep 23
S-8 POS
Registration of securities for employees (post-effective amendment)
22 Sep 23
S-8 POS
Registration of securities for employees (post-effective amendment)
22 Sep 23
S-8 POS
Registration of securities for employees (post-effective amendment)
22 Sep 23
6-K
IMV Inc. Announces Update on CCAA Proceedings and Sales and Investment Solicitation Process
26 Jul 23
Transcripts
IMVIQ
Earnings call transcript
2022 Q2
11 Aug 22
IMVIQ
Earnings call transcript
2022 Q1
13 May 22
IMVIQ
Earnings call transcript
2021 Q4
17 Mar 22
IMVIQ
Earnings call transcript
2021 Q2
11 Aug 21
IMVIQ
Earnings call transcript
2021 Q1
12 May 21
IMVIQ
Earnings call transcript
2020 Q4
17 Mar 21
IMVIQ
Earnings call transcript
2020 Q3
12 Nov 20
Latest ownership filings
SC 13G
ARMISTICE CAPITAL, LLC
14 Feb 23
SC 13G/A
FONDS DE SOLIDARITE DES TRAVAILLEURS DU QUEBEC
3 Feb 23
SC 13G/A
FONDS DE SOLIDARITE DES TRAVAILLEURS DU QUEBEC
21 Jul 21
SC 13G
Venrock Healthcare Capital Partners II, L.P.
30 Jul 20
SC 13G
FONDS DE SOLIDARITE DES TRAVAILLEURS DU QUEBEC
8 May 20
SC 13G/A
Beneficial ownership report (amended)
7 Feb 20
SC 13G
IMV Inc.
13 Feb 19
SC 13D
IMV Inc.
19 Jun 18
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q1 2023
11.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 16 |
Opened positions | 2 |
Closed positions | 5 |
Increased positions | 4 |
Reduced positions | 4 |
13F shares | Current |
---|---|
Total value | 342.19 mm |
Total shares | 1.29 mm |
Total puts | 0.00 |
Total calls | 21.70 k |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Fonds De Solidarite Des Travailleurs Du Quebec | 654.01 k | $0.00 |
Ruffer | 321.95 k | $166.80 mm |
Susquehanna International | 63.54 k | $33.99 mm |
National Bank of Canada | 53.86 k | $27.43 mm |
LexAurum Advisors | 51.10 k | $27.09 mm |
WFC Wells Fargo & Co. | 46.18 k | $24.91 mm |
First City Capital Management | 30.33 k | $24.94 mm |
Two Sigma Investments | 26.99 k | $14.31 mm |
RY Royal Bank Of Canada | 20.08 k | $10.00 mm |
First Manhattan | 6.64 k | $3.52 mm |